Aurobindo Pharma announced that the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) has recommended a grant of permission to its JV company Tergene.

The permission granted to its JV company is to manufacture and market a 15-valent Pneumococcal Polysaccharide Conjugate Vaccine with a three-dose schedule (3 +0) for administration into the pediatric age group of 6, 10 and 14 weeks. 

PCV15 vaccine was developed by Tergene Biotech and manufactured at AuroVaccines, which is a wholly owned subsidiary of Aurobindo Pharma with capabilities in vaccine development and manufacturing. Aurobindo Pharma Ltd holds an 80 per cent stake in the Joint Venture company, Tergene Biotech.